Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) suppress normal hematopoietic activity in part by enabling a pathogenic inflammatory milieu in the bone marrow. In this report, we show that elevation of angiopoietin-1 in myelodysplastic CD34+ stem-like cells is associated with higher...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Bachegowda, Lohith, Morrone, Kerry, Winski, Shannon L., Mantzaris, Ioannis, Bartenstein, Matthias, Ramachandra, Nandini, Giricz, Orsi, Sukrithan, Vineeth, Nwankwo, George, Shahnaz, Samira, Bhagat, Tushar, Bhattacharyya, Sanchari, Assal, Amer, Shastri, Aditi, Gordon-Mitchell, Shanisha, Pellagatti, Andrea, Boultwood, Jacqueline, Schinke, Carolina, Yu, Yiting, Guha, Chandan, Rizzi, James, Garrus, Jennifer, Brown, Suzy, Wollenberg, Lance, Hogeland, Grant, Wright, Dale, Munson, Mark, Rodriguez, Mareli, Gross, Stefan, Chantry, David, Zou, Yiyu, Platanias, Leonidas, Burgess, Laurence E., Pradhan, Kith, Steidl, Ulrich, Verma, Amit
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5398415/
https://ncbi.nlm.nih.gov/pubmed/27287719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-3062
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados